Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalised viral vector-based cancer vaccines, has raised €67.5 million in an oversubscribed Series C financing round. The proceeds will enable Nouscom to advance its pipeline and complete Phase II clinical trials with its cancer vaccine NOUS-209. Representatives from Andera Partners, Bpifrance and M Ventures, who led […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
